Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1648 1652 1671 1672
This examiner grants 68% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18026866 | CELL-FREE ANTIBODY ENGINEERING PLATFORM AND NEUTRALIZING ANTIBODIES FOR SARS-COV-2 | Non-Final OA | Massachusetts Institute of Technology |
| 18260029 | SPECIFIC DETECTION OF NUCLEIC ACID SEQUENCES USING ACTIVATE CLEAVE & COUNT (ACC) TECHNOLOGY | Non-Final OA | The Board of Trustees of the University of Illinois |
| 18734088 | VIRUS AND ANTIGEN PURIFICATION AND CONJUGATION | Non-Final OA | KBIO HOLDINGS LIMITED |
| 18526819 | DNA ANTIBODY CONSTRUCTS FOR USE AGAINST HIV | Non-Final OA | INOVIO PHARMACEUTICALS, INC. |
| 18556414 | GLYCAN MODIFIED SPIKE RECEPTOR BINDING DOMAIN NANOPARTICLES AND METHOD OF USE THEREOF AS A CORONAVIRUS DISEASE 2019 (COVID-19) VACCINE | Non-Final OA | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY |
| 18043944 | HA STEM VACCINE FOR HA ANTIBODY-POSITIVE TARGETS | Final Rejection | Intervet Inc. |
| 18002899 | EDIBLE CELL BASED VACCINES | Non-Final OA | Trustees of Tufts College |
| 18257808 | IMMUNOGENIC COMPOSITIONS | Non-Final OA | THE SCRIPPS RESEARCH INSTITUTE |
| 18283061 | Application of an Immunogenic or Vaccine Composition Against COVID-19 | Non-Final OA | EYE VACC |
| 18259841 | DEVICE AND SYSTEM FOR THE DETECTION OF ENVIRONMENTAL CONTAMINANTS | Non-Final OA | ITEL TELECOMUNICAZIONI S.R.L. (40%) |
| 18259893 | NOROVIRUS VIRUS-LIKE PARTICLE, IMMUNE COMPOSITION, OR KIT, AND USE THEREOF | Non-Final OA | GRAND THERAVAC LIFE SCIENCE (NANJING) CO., LTD. |
| 18032545 | FUSION PROTEIN AND VACCINE | Non-Final OA | THE RESEARCH FOUNDATION FOR MICROBIAL DISEASES OF OSAKA UNIVERSITY |
| 18018519 | ADAPTER POLYPEPTIDES AND METHODS OF USING THE SAME | Non-Final OA | SPOT BIOSYSTEMS LTD. |
| 18000858 | METHODS TO DETECT AND TREAT SARS-COV-2 (COVID19) INFECTION | Non-Final OA | THE U.S. GOVERNMENT AS REPRESENTED BY THE DEPT. OF VETERANS AFFAIRS |
| 18061045 | AUTOLOGOUS DENDRITIC CELL VACCINE KIT AND USES | Final Rejection | AIVITA BIOMEDICAL, INC |
| 17642570 | COMBINED EXPRESSION OF A CHIMERIC CD3 FUSION PROTEIN AND AN ANTI-CD3-BASED BISPECIFIC T CELL ACTIVATING ELEMENT | Non-Final OA | BIOTHEUS (SUZHOU) CO., LTD. |
| 17753603 | COMPOUNDS FOR THE INDUCTION OF ANTIGEN-SPECIFIC IMMUNE TOLERANCE | Non-Final OA | Anokion SA |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy